XML 61 R51.htm IDEA: XBRL DOCUMENT
v3.23.3

ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details) - USD ($) $ in Millions |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Feb. 22, 2023 | Jan. 30, 2023 | May 31, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Jul. 31, 2020 | Jun. 19, 2020
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  | $ 91 |  |  | $ 448 | $ 808 | $ 786 |  |
Other expense, net |  |  |  | 72 |  |  | $ 176 | 95 | $ 571 |  |
Arcellx, Inc | Global Strategic Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  | $ 212 |  |  |  |  |  |  |  |  |
Maximum potential future milestone payments |  | 835 |  |  |  |  |  |  |  |  |
Payments to acquire equity securities |  | $ 115 |  |  |  |  |  |  |  |  |
Revenue, performance obligation, percentage of U.S. profits |  | 50.00% |  |  |  |  |  |  |  |  |
Arcellx, Inc | Global Strategic Collaboration Agreement | Arcellx, Inc |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenue, performance obligation, percentage of U.S. profits |  | 50.00% |  |  |  |  |  |  |  |  |
Pionyr Immunotherapeutics Inc |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Estimated fair value |  |  |  |  |  |  |  |  |  |  | $ 70
Ownership percentage |  |  |  |  |  |  |  |  |  |  | 49.90%
Other expense, net |  |  |  |  |  | $ 70 |  |  |  |  |
Tizona Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  | 49.90% |
Estimated fair value |  |  |  |  |  |  |  |  |  | $ 41 |
Other expense, net |  |  |  | 41 |  |  |  |  |  |  |
XinThera, Inc |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Cash consideration |  |  | $ 200 |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  | $ 170 |  |  |  |  |  |
Maximum potential future milestone payments |  |  | $ 760 |  |  |  |  |  |  |  |
Tmunity Therapeutics |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Cash consideration | $ 300 |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  | $ 244 |  |  |  |  |
Maximum potential future milestone payments |  |  |  | $ 1,000 |  |  |  | $ 1,000 |  |  |

X
- Definition Payments For Asset Acquisitions + References No definition available. + Details
Name: | gild_PaymentsForAssetAcquisitions
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Future Milestone Payments, Maximum + References No definition available. + Details
Name: | gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Performance Obligation, Percentage Of U.S. Profits + References No definition available. + Details
Name: | gild_RevenuePerformanceObligationPercentageOfUSProfits
Namespace Prefix: | gild_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Fair value portion of investments accounted under the equity method. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_EquityMethodInvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_NonoperatingIncomeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_GlobalStrategicCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=gild_ArcellxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_XinTheraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |